Landau and coworkers provided evidence that CDX2 loss was observed not only in MSI-H BRAF-mutated colorectal cancers, but also in a subgroup of MSS BRAF-mutated colorectal cancers, characterized by an aggressive clinical phenotype and increased Cytokeratin 7 expression expression [86]. Here, BRAF is linked to colorectal cancer.